Type-1 Diabetes Treatment Market Proceeds To Witness Huge Upswing Over Assessmen

Posted by vinit sawant on March 24th, 2021

MARKET SYNOPSIS

The Global Type-1 Diabetes Treatment Market size is projected to grow from USD 5.6 Billion in 2018 to USD 9.6 Billion by 2025, registering a CAGR of 7.9%.

Type-1 diabetes is a chronic condition that requires lifelong medication. The onset of this condition usually occurs in childhood; it also affects obese and aged individuals.

This condition has been directly linked to a sedentary lifestyle, the adoption of which is widespread globally due to various societal, cultural, and economic factors. The rising prevalence of type-1 diabetes is driving the growth of the market.

Strict approvals processes are expected to hamper the growth of this market. However, this may be offset by the growing number of cases per year and increased government assistance for the management of the condition.

MARKET USP

The enhanced efficacy of rapid-acting insulin and rising number of specialty treatment centers for type-1 diabetes are aggressively driving the growth of the market.

SEGMENTATION

By Product

• Rapid-Acting Insulin: The rapid-acting insulin segment is expected to be the largest and fastest-growing during the review period. Usually taken before the ingestion of food or drink, rapid-action insulin is easy to introduce into the bloodstream and starts acting within 15 minutes of injection. The segment has been further classified as Admelog, Humalog, Novolog, and others.
• Short-Acting Insulin: Also known as regular insulin, it is included in the World Health Organization’s list of essential medicines.